{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0"},{"groupId":"OG001","value":"49.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2290"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"49.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2290"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2290"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Extreme pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6"},{"groupId":"OG001","value":"40.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2127"}],"units":"Participants"}],"title":"Week 13: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7"},{"groupId":"OG001","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2127"}],"units":"Participants"}],"title":"Week 13: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2127"}],"units":"Participants"}],"title":"Week 13: Extreme pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3"},{"groupId":"OG001","value":"43.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2062"},{"groupId":"OG001","value":"2080"}],"units":"Participants"}],"title":"Week 25: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3"},{"groupId":"OG001","value":"54.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2062"},{"groupId":"OG001","value":"2080"}],"units":"Participants"}],"title":"Week 25: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2062"},{"groupId":"OG001","value":"2080"}],"units":"Participants"}],"title":"Week 25: Extreme pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2106"}],"units":"Participants"}],"title":"EOT: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5"},{"groupId":"OG001","value":"47.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2106"}],"units":"Participants"}],"title":"EOT: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2106"}],"units":"Participants"}],"title":"EOT: Extreme pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3"},{"groupId":"OG001","value":"53.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1918"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"FU Month 18: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6"},{"groupId":"OG001","value":"44.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1918"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"FU Month 18: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"},{"groupId":"OG001","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1918"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"FU Month 18: Extreme pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7"},{"groupId":"OG001","value":"56.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1863"},{"groupId":"OG001","value":"1879"}],"units":"Participants"}],"title":"FU Month 24: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3"},{"groupId":"OG001","value":"41.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1863"},{"groupId":"OG001","value":"1879"}],"units":"Participants"}],"title":"FU Month 24: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1863"},{"groupId":"OG001","value":"1879"}],"units":"Participants"}],"title":"FU Month 24: Extreme pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5"},{"groupId":"OG001","value":"57.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1823"},{"groupId":"OG001","value":"1793"}],"units":"Participants"}],"title":"FU Month 36: No pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"40.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1823"},{"groupId":"OG001","value":"1793"}],"units":"Participants"}],"title":"FU Month 36: Moderate pain/discomfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1823"},{"groupId":"OG001","value":"1793"}],"units":"Participants"}],"title":"FU Month 36: Extreme pain/discomfort"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2400"},{"groupId":"OG001","value":"2404"}],"units":"Participants"}],"description":"EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \\[scored as 1\\], some or moderate problems \\[scored as 2\\], and extreme problems \\[scored as 3\\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding.","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT population. Number analyzed=participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Percentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain","type":"SECONDARY","unitOfMeasure":"percentage of participants"}